Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
Cameron R. Wolfe(Duke Medical Center), Anabela Cardoso(Eli Lilly (United States)), Diego López de Castilla(Evergreen Health Medical Center), Dante P. Melendez(University of Utah), Elizabeth Hohmann(Harvard University), Ryan C. Maves(Naval Medical Center San Diego), Nikhil Huprikar(Uniformed Services University of the Health Sciences), Barbara S. Taylor(The University of Texas at San Antonio Health Science Center), Emily R. Ko(Duke University Health System), Robert W. Finberg(Dana-Farber Cancer Institute), Thomas F. Patterson(National Institute of Allergy and Infectious Diseases), Susan Kline(University of Minnesota Medical Center), Nicole M. Iovine(University of Florida), Joslyn K. Strebe(Parkland Health & Hospital System), Guillermo M. Ruiz Palacios(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Alfredo Ponce‐de‐León(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Eu Suk Kim(Seoul National University Bundang Hospital), Nadine Rouphael(Emory University), Robert Grossberg(Albert Einstein College of Medicine), Hana M. El Sahly(Baylor College of Medicine), Allan Seibert(Providence Park Hospital), Kathleen G. Julian(Penn State Milton S. Hershey Medical Center), William R. Short(University of Pennsylvania), Uriel Sandkovsky, Justino Regalado Pineda(Instituto Nacional de Enfermedades Respiratorias), Aneesh K. Mehta(Emory University), Mark Holodniy(Stanford University), Daniel A. Sweeney(University of California System), Otto O. Yang(University of California, Los Angeles), Jesse L. Clark(University of Maryland, Baltimore), Michelle Harkins(University of New Mexico), Mamta K. Jain(The University of Texas Southwestern Medical Center), Alexandra W. Dretler, Vincent C. Marconi(Emory University), Catharine I. Paules(Penn State Milton S. Hershey Medical Center), Myoung‐don Oh(Seoul National University), Colleen F. Kelley(Emory University), Susan McLellan(Pediatrics and Genetics), Kevin A. Grimes(Methodist Hospital), Sarah B. Doernberg(Johns Hopkins University), Richard A. Mularski, John J. Engemann(Duke University), Carlos A. Gómez(Harvard University), Philip O. Ponce(The University of Texas at San Antonio Health Science Center), Pauline K. Park(University of Michigan), Eyad Almasri, Kay M Tomashek(National Institutes of Health), Angela R Branche(University of Rochester), LuAnn Larson(University of Nebraska Medical Center), Nathaniel Erdmann(University of Alabama)
Cited by 128
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k